Tianjin Chase Sun Pharmaceutical Co.,Ltd (SHE:300026)
China flag China · Delayed Price · Currency is CNY
3.280
-0.060 (-1.80%)
May 20, 2026, 12:04 PM CST

SHE:300026 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Operating Revenue
4,6464,9085,7576,0256,6037,656
Other Revenue
32.7332.7326.2484.3147.4414.63
4,6794,9415,7836,1096,6507,671
Revenue Growth (YoY)
-18.09%-14.55%-5.34%-8.14%-13.30%18.22%
Cost of Revenue
2,0052,1942,7932,8272,8263,267
Gross Profit
2,6732,7472,9893,2823,8244,403
Selling, General & Admin
2,1992,2822,5342,4632,7513,054
Research & Development
189.93192.26223.45209.81230.85196.59
Other Operating Expenses
54.5553.0548.7441.461.7276.44
Operating Expenses
2,4852,5692,8872,7673,1003,401
Operating Income
188.63177.81102.42515.52724.421,002
Interest Expense
-19.33-19.33-44.86-61.57-69.67-50.1
Interest & Investment Income
10.8410.8417.3119.3114.1811.38
Currency Exchange Gain (Loss)
-2.74-2.743.922.4117.62-6.34
Other Non Operating Income (Expenses)
-38.32-35.84-22.2-18.49-35.65-26.86
EBT Excluding Unusual Items
138.76130.7356.59457.19650.91930.58
Impairment of Goodwill
-39.6-39.6-17.34-23.52--58.18
Gain (Loss) on Sale of Investments
-3.66-3.66-5.63-1.4--22.98
Gain (Loss) on Sale of Assets
0.720.71.081.060.01-2.87
Asset Writedown
-5.62-4.98-30.33-4.05-2.36-9.35
Other Unusual Items
-0.55-0.5549.62177.5467.8216.99
Pretax Income
90.0482.6553.98606.82716.37854.18
Income Tax Expense
61.0860.4231.04105.2595.14183.32
Earnings From Continuing Operations
28.9622.2222.95501.57621.23670.85
Minority Interest in Earnings
-5.08-3.73-1.485.063.0116.47
Net Income
23.8818.521.47506.63624.24687.32
Net Income to Common
23.8818.521.47506.63624.24687.32
Net Income Growth
0.86%-13.84%-95.76%-18.84%-9.18%19.87%
Shares Outstanding (Basic)
1,9171,8502,1472,9802,9732,988
Shares Outstanding (Diluted)
1,9171,8502,1472,9802,9732,988
Shares Change (YoY)
-11.84%-13.84%-27.97%0.26%-0.53%-0.98%
EPS (Basic)
0.010.010.010.170.210.23
EPS (Diluted)
0.010.010.010.170.210.23
EPS Growth
14.42%--94.12%-19.05%-8.70%21.05%
Free Cash Flow
684.14681.09659.121,183-24.93-285.85
Free Cash Flow Per Share
0.360.370.310.40-0.01-0.10
Dividend Per Share
0.0100.0100.0300.0300.0300.040
Dividend Growth
-66.67%-66.67%---25.00%-
Gross Margin
57.14%55.59%51.69%53.73%57.50%57.40%
Operating Margin
4.03%3.60%1.77%8.44%10.89%13.07%
Profit Margin
0.51%0.37%0.37%8.29%9.39%8.96%
Free Cash Flow Margin
14.62%13.78%11.40%19.36%-0.38%-3.73%
EBITDA
455.95450.9398.59807.69974.091,217
EBITDA Margin
9.75%9.13%6.89%13.22%14.65%15.86%
D&A For EBITDA
267.32273.09296.18292.17249.67214.2
EBIT
188.63177.81102.42515.52724.421,002
EBIT Margin
4.03%3.60%1.77%8.44%10.89%13.07%
Effective Tax Rate
67.84%73.11%57.49%17.34%13.28%21.46%
Revenue as Reported
4,9414,9415,7836,1096,6507,671
Advertising Expenses
-13.378.69.1512.621.21
Source: S&P Global Market Intelligence. Standard template. Financial Sources.